Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.58 |
| ▸ | PARP1 | P09874 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6610458 | 0.94 | AR (0.58) | ARPARP1LMNATSHRPRMT5 | |
| SCHEMBL2429268 | 0.88 | LMNA (0.70) | ARPARP1LMNATSHRPRMT5 | |
| SCHEMBL905630 | 0.86 | AR (0.79) | ARPARP1LMNATSHRPRMT5 | |
| SCHEMBL2530542 | 0.81 | PARP1 (0.54) | ARPARP1LMNATSHRPRMT5 | |
| SCHEMBL5555992 | 0.77 | PARP1 (0.54) | ARPARP1LMNATSHRPRMT5 | |
| SCHEMBL6608381 | 0.77 | PARP1 (0.54) | ARPARP1LMNATSHRPRMT5 | |
| SCHEMBL6586097 | 0.77 | ENPP1 (0.63) | ARPARP1LMNATSHRENPP1 | |
| SCHEMBL12955389 | 0.76 | AR (0.72) | ARPARP1LMNATSHRPRMT5 | |
| SCHEMBL905666 | 0.75 | PARP1 (0.60) | ARPARP1LMNATSHRENPP1 | |
| SCHEMBL905602 | 0.75 | PARP1 (0.76) | ARPARP1LMNATSHRENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0970070-B1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-6710047-B2 | INHIBIT THE ACTIVITY OF THE VEGF RECEPTOR TYROSINE KINASE AND THE GROWTH OF TUMOURS | NOVARTIS AG (CH) | 2004-03-23 | — | — | US | disclosed |
| US-20030191129-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2003-10-09 | — | — | US | disclosed |
| US-6514974-B2 | 1-(4-Chloroanilino)-4-(4-pyridylmethyl)phthalazine for example | NOVARTIS AG (CH) | 2003-02-04 | — | — | US | disclosed |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2002-07-11 | — | — | US | disclosed |
| US-6258812-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS AND CARDIOVASCULAR DISORDERS | NOVARTIS AG (CH) | 2001-07-10 | — | — | US | disclosed |
| EP-0970070-A1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | Novartis AG (CH) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998035958-A1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191129-A1 | Phthalazines with angiogenesis inhibiting activity | PGF, VEGFA, FLT4 | AR 908/4885PARP1 3676/4885LMNA 3374/4885 |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | PGF, VEGFA, FLT4 | AR 807/4885PARP1 3475/4885LMNA 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.